What question did this study set out to answer?

To identify and isolate potent broadly neutralizing monoclonal antibodies from HIV-1-infected individuals to uncover new conserved epitopes for rational vaccine design.

September 3, 2009Science

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

View Full Paper

Ask AI

Bookmark

Authors

LWLaura M. WalkerChildren's Hospital of Philadelphia SPSanjay PhogatUniversity of Delhi PCPo-Ying Chan-HuiTheraclone Sciences (United States)

Discussion

Member takes

Implication

Experimental study uncovers potent broadly neutralizing antibodies targeting gp120 in an HIV-1-infected African donor, highlighting a new target for vaccine design.

Key Points

To identify and isolate potent broadly neutralizing monoclonal antibodies from HIV-1-infected individuals to uncover new conserved epitopes for rational vaccine design.
Screened serum neutralization breadth across approximately 1,800 HIV-1-infected donors primarily exposed to non-clade B viral strains.
Performed high-throughput neutralization screens of culture supernatants from about 30,000 activated memory B cells obtained from a selected clade A-infected African donor.
Isolated two potent monoclonal antibodies displaying broad neutralization capacity across diverse HIV-1 strains.
Mapped the target broadly neutralizing epitope to conserved segments within the variable loops of the gp120 subunit, preferentially presented on the native trimeric Envelope protein.

Cite This Study

Walker et al. (2009) studied this question.

synapsesocial.com/papers/69dff632ca6b6a2615860641 https://doi.org/10.1126/science.1178746

View Full Paper

Ask AI

Bookmark

September 3, 2009Science

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

View Full Paper

Ask AI

Bookmark

Authors

LWLaura M. WalkerChildren's Hospital of Philadelphia SPSanjay PhogatUniversity of Delhi PCPo-Ying Chan-HuiTheraclone Sciences (United States)

Discussion

Member takes

Implication

Experimental study uncovers potent broadly neutralizing antibodies targeting gp120 in an HIV-1-infected African donor, highlighting a new target for vaccine design.

Key Points

To identify and isolate potent broadly neutralizing monoclonal antibodies from HIV-1-infected individuals to uncover new conserved epitopes for rational vaccine design.
Screened serum neutralization breadth across approximately 1,800 HIV-1-infected donors primarily exposed to non-clade B viral strains.
Performed high-throughput neutralization screens of culture supernatants from about 30,000 activated memory B cells obtained from a selected clade A-infected African donor.
Isolated two potent monoclonal antibodies displaying broad neutralization capacity across diverse HIV-1 strains.
Mapped the target broadly neutralizing epitope to conserved segments within the variable loops of the gp120 subunit, preferentially presented on the native trimeric Envelope protein.

Cite This Study

Walker et al. (2009) studied this question.

synapsesocial.com/papers/69dff632ca6b6a2615860641 https://doi.org/10.1126/science.1178746

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark